Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal (CRE NIS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00781560
First received: October 28, 2008
Last updated: August 6, 2009
Last verified: August 2009
  Purpose

This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in "real world"; and to evaluate the percentage of hyperlipidemia patients who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) following 8-week treatment by Crestor® 5mg or 10mg


Condition
Hyperlipidemia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Cross-sectional Study to Survey the Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and the Rate of Patients (on Treatment) Achieving the Hyperlipidaemia Treatment Goal With Crestor 5mg to 10mg for 8 Weeks

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists [ Time Frame: 1 time ] [ Designated as safety issue: No ]
  • the control rate of patients reaching target LDL-C level [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • the percent change from baselines in TC, TG, HDL-C [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • the percentage of hyperlipidemia patients in different risk categories who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 2575
Study Start Date: October 2008
Study Completion Date: July 2009
Groups/Cohorts
1
patients being diagnosed as dyslipidemia but not receiving Crestor®
2
hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who has been diagnosed as hypercholesterolemia and decided by physician to use Crestor® 5mg or 10mg or other regimens (TLC or other lipid-lowering agents)

Criteria

Inclusion Criteria:

  • Diagnosed as dyslipidemia by doctors
  • Having lipids test and record within one months
  • Diagnosed as hypercholesterolemia or mixed dyslipidaemias and has been prescribed Crestor® 5mg or 10mg

Exclusion Criteria:

  • Unable or unwilling to provide the Inform Consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00781560

Locations
China, Beijing
Research Site
Beijing, Beijing, China
China, Guangdong
Research Site
Chenzhen, Guangdong, China
Research Site
Guangzhou, Guangdong, China
China, Heilongjiang
Research Site
Harbin, Heilongjiang, China
China, Henan
Research Site
ZhengZhou, Henan, China
China, Jiangsu
Research Site
Nanjing, Jiangsu, China
China, Liaoning
Research Site
Shenyang, Liaoning, China
China, Shandong
Research Site
Jinan, Shandong, China
Research Site
Qingdao, Shandong, China
China, Shanghai
Research Site
Shanghai, Shanghai, China
China, Shanxi
Research Site
Xi'an, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Tianjin
Research Site
Tianjin, Tianjin, China
China, Zhejiang
Research Site
Hangzhou, Zhejiang, China
Reseearch Site
Ningbo, Zhejiang, China
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Karen Atkin Astrazeneca China R&D
Principal Investigator: Zhu Junren Fudan University
  More Information

No publications provided

Responsible Party: Karen Atkin/ VP. China R&D, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00781560     History of Changes
Other Study ID Numbers: NIS-CCN-CRE-2008/1
Study First Received: October 28, 2008
Last Updated: August 6, 2009
Health Authority: China: Food and Drug Administration

Keywords provided by AstraZeneca:
Hyperlipidemia
Chinese National Adult Lipid Treatment Guideline (2007)
Crestor®

Additional relevant MeSH terms:
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014